METHODS FOR TREATING PRIMARY MEMBRANOUS NEPHROPATHY
Provided here are methods of treating primary membranous nephropathy in a patient in need thereof, comprising administering to said patient a BTK inhibitor, e.g., (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof.
1 . A method of treating primary membranous nephropathy (pMN) comprising administering to a patient having primary membranous nephropathy a therapeutically effective amount of a Bruton's Tyrosine Kinase (BTK) inhibitor.
2 . The method of claim 1 , wherein the Bruton's Tyrosine Kinase inhibitor is Compound A having the name of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or the following structure:
or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof.
3 . The method of claim 2 , wherein the patient is identified as having (i) an elevated level of an autoantibody specific for an antigen or (ii) kidney tissue comprising an elevated level of the antigen, wherein the antigen is PLA2R, or THSD7A.
4 . The method of any one of claims 1-3 , wherein the patient is identified as biopsy confirmed primary membranous nephropathy and with persistent nephrotic syndrome after run-in period.
5 . The method of any one of claims 1-4 , wherein the patient is identified as having an elevated level of the autoantibody.
6 . The method of any one of claims 1-5 , wherein the level of autoantibodies present within the patient is reduced by at least about 5 percent, at least about 25 percent, or at least about 50 percent following the administering step.
7 . The method of any one of claims 3-6 , wherein the antigen is PLA2R.
8 . The method of claim 7 , wherein the patient is a PLA2R mediated patient with primary membranous nephropathy.
9 . The method of claim 7 , wherein the level of an autoantibody specific for PLA2R is more than about 20 RU/mL, about 40 RU/mL, about 50 RU/mL, about 60 RU/mL, or about 80 RU/mL in serum prior to the administering step.
10 . The method of any one of claims 3-6 , wherein the antigen is THSD7A.
11 . The method of claim 10 , wherein the patient is a THSD7A mediated patient with primary membranous nephropathy.
12 . The method of any one of claims 1-3 , wherein the patient is identified as having the kidney tissue comprising an elevated level of the antigen.
13 . The method of claim 12 , wherein the level of the antigen present within kidney tissue is reduced by at least about 5 percent, at least about 25 percent, or at least about 50 percent following the administering step.
14 . The method of any one of claims 1-3 and 11-13 , wherein the antigen is PLA2R.
15 . The method of any one of claims 1-3 and 11-13 , wherein the antigen is THSD7A.
16 . The method of any one of claims 2-15 , wherein Compound A or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof is administered one, two, or three times a day.
17 . The method any one of claims 2-16 , wherein Compound A or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof is administered from about 40 mg to about 320 mg per day.
18 . The method of claim 17 , wherein Compound A or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof is administered at about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, or about 320 mg per day.
19 . The method of claim 18 , wherein Compound A or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof is administered at about 40 mg, about 80 mg, about 160 mg, or about 320 mg per day.
20 . The method of claim 19 , wherein the method comprises administering to the patient Compound A at a dose of about 160 mg twice a day (BID) or about 160 mg once a day (QD).
21 . The method of claim 19 , wherein the method comprises administering to the patient Compound A at a dose of about 160 mg twice a day (BID) or about 160 mg once a day (QD) orally.
22 . The method of claim 19 , wherein the method comprises administering to the patient Compound A at a dose of about 160 mg twice a day (BID) orally.
23 . The method of claim 19 , wherein the method comprises administering to the patient Compound A at a dose of about 160 mg once a day (QD) orally.
24 . The method of any one of claims 1-20 , wherein the patient achieves a partial remission, or a complete remission.
25 . The method of claim 24 , wherein the patient achieves a partial remission.
26 . The method of claim 24 , wherein the patient achieves a complete remission.
27 . The method of any one of claims 1-20 , wherein the method provides a plasma Compound A AUC 0-24h between about 1,607 ng*h/ml and about 2,984 ng*h/ml in the patient.
28 . The method of any one of claims 1-20 , wherein the method provides a plasma Compound A AUC 0-∞ , between about 843 ng*h/ml and about 3,786 ng*h/ml in the patient.